文献速递乳腺癌

氟维司群对比阿那曲唑在未接受内分泌治疗激素受体阳性晚期乳腺癌女性中的研究:III期FALCON试验最终总生存分析

Fulvestrant Versus Anastrozole in Endocrine Therapy-Naïve Women With Hormone Receptor-Positive Advanced Breast Cancer: Final Overall Survival in the Phase III FALCON Trial.
PubMed 文献 · J Clin Oncol · 2025-01-07

FALCON是一项随机III期试验,在未接受内分泌治疗、激素受体阳性/人表皮生长因子受体2阴性的绝经后晚期乳腺癌女性中,比较氟维司群与阿那曲唑。最终总生存分析显示两组无显著差异(中位44.8个月 vs 42.7个月;HR 0.97,95%CI 0.77-1.21;P=0.7579)。在非内脏疾病患者中,氟维司群组相对死亡风险呈现15%降低的趋势。

要点

  • 最终OS分析显示氟维司群与阿那曲唑无显著差异,中位OS分别为44.8个月和42.7个月。
  • 非内脏疾病患者中,氟维司群组中位OS为65.2个月,阿那曲唑组为47.8个月,HR 0.85。
  • FALCON数据与已发表的氟维司群及其他内分泌治疗在非内脏疾病亚组中长期临床获益的证据一致。

核心结论

  • FALCON最终总生存分析显示,在未接受内分泌治疗的激素受体阳性/人表皮生长因子受体2阴性绝经后晚期乳腺癌女性中,氟维司群与阿那曲唑的总生存无显著差异(中位44.8个月 vs 42.7个月;HR 0.97,95%CI 0.77-1.21;P=0.7579)。
  • 在非内脏疾病患者中,氟维司群组相对阿那曲唑组呈现死亡风险降低15%的趋势(中位OS 65.2个月 vs 47.8个月;HR 0.85,95%CI 0.60-1.20)。

研究设计与样本

  • 随机III期FALCON试验,纳入未接受内分泌治疗、激素受体阳性/人表皮生长因子受体2阴性的绝经后晚期乳腺癌女性。
  • 最终OS分析在≥65%成熟度且距最后一位患者入组≥8年时触发,分析为描述性,采用名义P值(单侧α阈值0.01845)。
  • 数据截止2022年7月11日,462例患者中314例(68.0%)死亡(氟维司群组157/230[68.3%],阿那曲唑组157/232[67.7%])。

主要发现

  • 最终OS分析显示氟维司群与阿那曲唑无显著差异(中位44.8个月 vs 42.7个月;HR 0.97,95%CI 0.77-1.21;P=0.7579)。
  • 非内脏疾病患者(n=208)中,氟维司群组相对阿那曲唑组显示死亡风险降低15%的趋势(中位OS 65.2个月 vs 47.8个月;HR 0.85,95%CI 0.60-1.20)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 最终OS分析为描述性,采用名义P值(单侧α阈值0.01845)。
  • 非内脏疾病亚组中氟维司群组相对阿那曲唑组死亡风险降低的趋势未达统计学显著(HR 0.85,95%CI 0.60-1.20)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The randomized phase III FALCON trial demonstrated significant improvement in progression-free survival (PFS) with fulvestrant versus anastrozole in postmenopausal women with endocrine therapy-naïve, hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer. Herein, the prespecified final overall survival (OS) analysis is reported. After the primary PFS analysis, data were collected on survival, serious adverse events, and health-related quality of life. The final OS analysis was triggered at ≥65% maturity and ≥8 years since the last patient was enrolled. Analyses were descriptive with nominal P values (one-sided α threshold .01845). At the data cutoff (July 11, 2022), 314 (68.0%) of 462 patients had died (fulvestrant, 157/230 [68.3%], anastrozole, 157/232 [67.7%]). The final OS analysis of FALCON demonstrated no significant difference between fulvestrant and anastrozole (medians, 44.8 and 42.7 months, respectively; hazard ratio [HR], 0.97 [95% CI, 0.77 to 1.21]; P = .7579). Among patients with nonvisceral disease (n = 208), a trend showed a 15% reduction in the relative risk of death with fulvestrant versus anastrozole (median OS, 65.2 v 47.8 months; HR, 0.85 [95% CI, 0.60 to 1.20]). Data from FALCON are consistent with published evidence of long-term clinical benefit with fulvestrant and other endocrine therapies in the subset of patients with nonvisceral disease.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Robertson JFR, Shao Z, Noguchi S, et al. Fulvestrant Versus Anastrozole in Endocrine Therapy-Naïve Women With Hormone Receptor-Positive Advanced Breast Cancer: Final Overall Survival in the Phase III FALCON Trial. J Clin Oncol. 2025. PMID: 39772884. doi:10.1200/JCO.24.00994

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。